Alnylam Pharmaceuticals, Inc Forecast, price target & analysts
Alnylam Pharmaceuticals, Inc Target price 2025 - Analyst rating & recommendation
Alnylam Pharmaceuticals, Inc Classifications & Recommendation:
Alnylam Pharmaceuticals, Inc Price Target
| Target Price | $334.56 |
| Price | $322.83 |
| Potential |
3.63%
register free of charge
|
| Number of Estimates | 32 |
|
32 Analysts have issued a price target Alnylam Pharmaceuticals, Inc 2026 .
The average Alnylam Pharmaceuticals, Inc target price is $334.56.
This is
3.63%
register free of charge
$525.00
62.62%
register free of charge
$214.12
33.67%
register free of charge
|
|
| A rating was issued by 39 analysts: 30 Analysts recommend Alnylam Pharmaceuticals, Inc to buy, 8 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Alnylam Pharmaceuticals, Inc stock has an average upside potential 2026 of
3.63%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.25 | 2.94 |
| 22.97% | 30.77% | |
| EBITDA Margin | -5.35% | 5.57% |
| 57.15% | 204.17% | |
| Net Margin | -12.37% | -6.10% |
| 48.62% | 50.70% |
35 Analysts have issued a sales forecast Alnylam Pharmaceuticals, Inc 2025 . The average Alnylam Pharmaceuticals, Inc sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Alnylam Pharmaceuticals, Inc EBITDA forecast 2025. The average Alnylam Pharmaceuticals, Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
36 Alnylam Pharmaceuticals, Inc Analysts have issued a net profit forecast 2025. The average Alnylam Pharmaceuticals, Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.18 | -1.38 |
| 38.07% | 36.70% | |
| P/E | negative | |
| EV/Sales | 13.77 |
36 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast for earnings per share. The average Alnylam Pharmaceuticals, Inc EPS is
This results in the following potential growth metrics and future valuations:
Alnylam Pharmaceuticals, Inc...
Current Alnylam Pharmaceuticals, Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Jun 26 2025 |
| BMO Capital |
Locked
➜
Locked
|
Locked | Jun 24 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Jun 12 2025 |
| UBS |
Locked
➜
Locked
|
Locked | May 02 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 02 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Jun 26 2025 |
|
Locked
BMO Capital:
Locked
➜
Locked
|
Jun 24 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jun 12 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
May 02 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 02 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Apr 11 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 09 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
